Business Context and Reporting Period
This Form 8-K was filed by Silexion Therapeutics Corp on September 25, 2025, reporting events occurring on September 23, 2025. The filing addresses the company's status regarding its listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide standard financial statements such as revenue, profit, or cash flow. However, it discloses the following equity-related figures:
- Shareholders' Equity: Approximately $9.41 million as of September 15, 2025.
- Equity Increase: Financing transactions increased pro forma shareholders' equity by $10.3 million as of July 31, 2025.
- Minimum Bid Price: The company's ordinary shares have traded above the required $1.00 per share threshold since a reverse split.
Material Changes
The primary material change is the restoration of compliance with Nasdaq listing requirements following a period of deficiency:
- Equity Compliance: The company met the $2.5 million shareholders' equity requirement by September 19, 2025, following a favorable decision from the Nasdaq Hearings Panel in July 2025.
- Bid Price Compliance: After receiving notice of a bid price deficiency in July 2025, the company executed a 1-for-15 reverse share split on July 29, 2025, resulting in share prices exceeding the $1.00 minimum.
Outlook, Risks, and Contingencies
Nasdaq has confirmed the company's compliance but imposed a mandatory monitoring period:
- Monitoring Period: The company is subject to a mandatory panel monitor until September 23, 2026.
- Delisting Risk: If the company falls out of compliance with the Equity Requirement during this one-year period, it will not be permitted to submit a compliance plan or receive additional cure time. Instead, Nasdaq would issue a "Delist Determination Letter," subject to a potential hearing request.
Investor Verification Checklist
- Verify the current market price of SLXN to ensure it remains above the $1.00 minimum bid price.
- Review the company's most recent financial statements to confirm the $9.41 million shareholders' equity figure remains stable.
- Monitor future 8-K filings for any notices of non-compliance during the mandatory monitoring period ending September 23, 2026.
- Confirm the status of the financing transactions mentioned that contributed to the equity increase.